While targeting inflammation potentially via ATM activity may prove useful for patients with established DCM owing to prelamin A accumulation, the immediate translational aspect of this study lies in the implications for the treatment of HIV-associated cardiomyopathy patients, for whom a change of therapy may have a beneficial outcome in the clinic. This evidence concerns the gene ATM and familial dilated cardiomyopathy.